Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Product Portfolio
Our Process
Therapeutic Areas
Patient Assistance
Product Related Issues
About Us
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to Healthcare Professionals
Payments to Healthcare Organizations
Physician Payments - Sunshine Act
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
March
Media Release
/
Mar 18, 2020
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Read More
Featured News
/
Mar 11, 2020
Novartis provides update on use and safety of Beovu® in patients with wet AMD
Read More
February
Featured News
/
Feb 12, 2020
Novartis launches new Preferred Firm Program for legal services
Read More
Media Release
/
Feb 11, 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Read More
January
Media Release
/
Jan 16, 2020
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Read More
Story
/
Jan 09, 2020
Sourcing innovation, strategically
Phil Gotwals talks about his vision for the future of business development for research.
Read More
2019
December
Media Release
/
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Read More
Media Release
/
Dec 09, 2019
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Read More
November
Media Release
/
Nov 17, 2019
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Read More
Media Release
/
Nov 15, 2019
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
2
of 5
Page
3
of 5
Current page
4
of 5
Page
5
of 5
Page
6
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News
